...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans
【24h】

HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans

机译:HLA-B * 35:01等位基因是一种潜在的生物标志物,用于预测人类在人类中的多粒子致血液诱导的肝损伤

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Polygonum multiflorum (PM) is a well-known Chinese herbal medicine that has been reported to induce inflammation-associated idiosyncratic liver injury. This study aimed to identify the genetic basis of susceptibility to PM-drug-induced liver injury (PM-DILI) and to develop biological markers for predicting the risk of PM-DILI in humans. The major histocompatibility complex (MHC) regions of 11 patients with PM-DILI were sequenced, and all human leukocyte antigen (HLA)-type frequencies were compared to the Han-MHC database. An independent replication study that included 15 patients with PM-DILI, 33 patients with other DILI, and 99 population controls was performed to validate the candidate allele by HLA-B PCR sequence-based typing. A prospective cohort study that included 72 outpatients receiving PM for 4 weeks was designed to determine the influence of the risk allele on PM-DILI. In the pilot study, the frequency of HLA-B*35:01 was 45.4% in PM-DILI patients compared with 2.7% in the Han Chinese population (odds ratio [OR], 30.4; 95% confidence interval [CI], 11.7-77.8; P = 1.9 x 10(-10)). In the independent replication study and combined analyses, a logistic regression model confirmed that HLA-B*35:01 is a high-risk allele of PM-DILI (PM-DILI versus other DILI, OR, 86.5; 95% CI, 14.2-527.8, P = 1.0 x 10(-6); and PM-DILI versus population controls, OR, 143.9; 95% CI, 30.1-687.5, P = 4.8 x 10(-10)). In the prospective cohort study, an asymptomatic increase in transaminase levels was diagnosed in 6 patients, representing a significantly higher incidence (relative risk, 8.0; 95% CI, 1.9-33.2; P < 0.02) in the HLA-B*35:01 carriers (37.5%) than in the noncarriers (4.7%). Conclusion: The HLA-B*35:01 allele is a genetic risk factor for PM-DILI and a potential biomarker for predicting PM-DILI in humans.
机译:Polygonum multiflorum(PM)是据报道的众所周知的中草药诱导炎症相关的特质肝损伤。本研究旨在识别对PM-药物诱导的肝损伤(PM-DIRI)易感性的遗传基础,并开发用于预测人类PM-DILI风险的生物学标志物。将11例PM-DILI患者的主要组织相容性复合物(MHC)区域测序,并将所有人白细胞抗原(HLA)型频率与HAN-MHC数据库进行比较。一项独立的复制研究,包​​括15名PM-DILI,33例其他帝力患者和99名人口对照的患者进行了通过HLA-B PCR序列的键入候选等位基因进行验证。旨在将PM持续4周的72位门诊患者包含72例的预期队列研究旨在确定风险等位基因对PM-DILI的影响。在试验研究中,PM-DIRI患者HLA-B * 35:01的频率为45.4%,而汉族人群(赔率比[或],30.4; 95%置信区间[CI],11.7 -77.8; p = 1.9 x 10(-10))。在独立的复制研究和组合分析中,Logistic回归模型证实,HLA-B * 35:01是PM-​​DIRI的高风险等位基因(PM-DILI与其他DIRI,或86.5; 95%CI,14.2- 527.8,p = 1.0 x 10(-6);和PM-DILI与人口控制,或143.9; 95%CI,30.1-687.5,P = 4.8 x 10(-10))。在预期队列研究中,在6名患者中诊断了转氨酶水平的无症状增加,其发病率显着更高(相对风险,8.0; 95%CI,1.9-33.2; P <0.02)在HLA-B * 35:01载体(37.5%)比非载体(4.7%)。结论:HLA-B * 35:01等位基因是PM-DIRI的遗传危险因素,以及用于预测人类PM-DILI的潜在生物标志物。

著录项

  • 来源
  • 作者单位

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Henan Univ Tradit Chinese Med Affiliated Hosp 1 Zhengzhou Henan Peoples R China;

    Henan Univ Tradit Chinese Med Affiliated Hosp 1 Zhengzhou Henan Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

    Hunan Key Lab Bioanal Complex Matrix Samples Changsha Hunan Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Gen Hosp PLA Med Ctr 5 100 West 4th Ring Rd Beijing Peoples R China;

    Cent S Univ Xiangya Hosp Dept Clin Pharmacol Changsha Hunan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号